Intimation regarding execution of Agreement to Transfer Business with Sunways (India) Private Limited
M&A
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 30 Apr 2026, 07:53 PM IST · BSE ID: 14531216-07a7-4a9f-b389-e961ea7a0be6
View Original BSE Filing (PDF)
💡
In Simple Terms
Indoco is selling its eye care business division to another company for Rs. 110 Crore in cash, completing paperwork today.
🤖 AI Summary
- Agreement to Transfer Business executed 30th April 2026 for Rs. 110 Crores
- Ophthalmic division generated Rs. 47.79 Crores revenue in FY25 — 3.2% of company total
- Buyer is Sunways (India) Private Limited with FY25 standalone revenue Rs. 137.42 Crores
- Sale covers India, French West Africa, Cameroon, Congo, Gabon, Kenya, Botswana, Tanzania, Zambia, Zimbabwe, Namibia
- Transaction completion expected in approximately three months subject to conditions precedent
🔢 Key Numbers — exact figures from BSE filing, not rounded
Sale consideration
Rs. 110 Crores
Ophthalmic division FY25 revenue
Rs. 47.79 Crores
Division contribution to standalone revenue
3.2%
Buyer FY25 revenue (standalone)
Rs. 137.42 Crores
Expected completion timeline
Approximately 3 months
🏢 How This Affects the Company
Ophthalmic division represented only 3.2% of standalone revenue (Rs. 47.79 Crores in FY25). Divestment removes a non-core, lower-contribution unit. Core pharma business continues unaffected.
Rs. 110 Crores gross consideration received, subject to adjustments. Removes Rs. 47.79 Crores annual revenue stream but generates one-time cash inflow. Net impact on standalone earnings depends on division profitability and adjustment terms.
Divestment eliminates separate ophthalmic operations, supply chain, and associated workforce in specified territories. Remaining core pharmaceutical operations continue independently.
Transaction completion contingent on conditions precedent in ATB. Failure to satisfy conditions could delay or terminate sale. Post-completion, company loses footprint in ophthalmic segment across 11 territories.
👥 What This Means For Shareholders
✅
Action Required
No action required. Transaction completion will be reported via subsequent regulation 30 disclosure.
👤
Who Is Affected
All shareholders benefit proportionally from Rs. 110 Crore cash inflow to balance sheet. No selective impact identified in filing.
🔍
Management Signal
Management prioritizes core pharmaceutical business by divesting lower-margin, non-core ophthalmic operations in multiple territories.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Regulation 30 disclosure on ATB execution confirmation with exact agreement date
Q1 FY27 results — verify standalone revenue excludes ophthalmic division
Completion filing per Regulation 30 — confirm Rs. 110 Crore cash receipt and final adjustments
MEDIUM RISK
Transaction completion subject to conditions precedent not detailed in filing. Adjustment mechanism for Rs. 110 Crore consideration not specified. Three-month timeline adds execution uncertainty.
💡 Investor Takeaway
Indoco has sold its ophthalmic division to Sunways for Rs. 110 Crores, generating one-time cash inflow. Division contributed Rs. 47.79 Crores revenue in FY25 (3.2% of standalone total). Completion expected in three months, subject to conditions precedent in the agreement.
⚖️ Strengths & Concerns
✅ Positives
- Clear asset divestment at Rs. 110 Crores generates liquidity for core business reinvestment
- Buyer Sunways has established operations — FY25 revenue Rs. 137.42 Crores — suggests capability
⚠️ Concerns
- Ophthalmic division sale removes revenue stream entirely despite 3.2% contribution to standalone revenue
- Transaction completion depends on undefined conditions precedent — three-month timeline remains subject to satisfaction
📅 Company Track Record
Prior intimation filed 30th April 2026 announced strategic transfer of ophthalmic division to Sunway (same date). Today's filing confirms execution of formal Agreement to Transfer Business with Sunways (India) Private Limited. Past financial track record of Indoco's ophthalmic division not detailed in prior public filings reviewed.
Based on publicly available historical data. For context only.